Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, i...
Main Authors: | Qasim Akram, Mark Roberts, Chester Oddis, Arianne Herrick, Hector Chinoy |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2016-03-01
|
Series: | Rheumatology |
Subjects: | |
Online Access: | http://www.termedia.pl/Rituximab-induced-neutropenia-in-a-patient-with-inflammatory-myopathy-and-systemic-sclerosis-overlap-disease,18,27173,1,1.html |
Similar Items
-
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
by: Fernando Henrique Carlos de Souza, et al.
Published: (2018-09-01) -
The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature
by: S. Barsotti, et al.
Published: (2018-07-01) -
Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus
by: Mervat E Behiry, et al.
Published: (2019-01-01) -
Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01) -
Brachio-cervical inflammatory myopathy associated with systemic sclerosis. Case series and review of literature
by: C.S.R. Araujo, et al.
Published: (2021-08-01)